UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000054184
Receipt number R000061871
Scientific Title Study of formula milk with breast milk-derived new ingredient (nicotinamide mononucleotide) on energy metabolism of baby: multicenter, double-blinded, randomized, commercial product-controlled trial
Date of disclosure of the study information 2024/04/18
Last modified on 2024/04/18 11:46:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of formula milk with breast milk-derived new ingredient (nicotinamide mononucleotide) on energy metabolism of baby: multicenter, double-blinded, randomized, commercial product-controlled trial

Acronym

SMILE-Baby study

Scientific Title

Study of formula milk with breast milk-derived new ingredient (nicotinamide mononucleotide) on energy metabolism of baby: multicenter, double-blinded, randomized, commercial product-controlled trial

Scientific Title:Acronym

SMILE-Baby study

Region

Japan


Condition

Condition

Healthy infant

Classification by specialty

Child

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate exploratorily the effect of NMD-containing infant milk fomula on blood NAD levels of infant by targeting artificially or mixed-fed infants and their mothers

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood NAD concentration

Key secondary outcomes

1. NMN metabolite in blood or urine of infants
2. Blood biochemical laboratory test values of infants
3. Body measurements (hight, weight, etc.)
4. Frequeycy of adverse events in infants that is considered to be related with the consumption of the study milk


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Active

Stratification


Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Study infant milk fomula group
- consume study infant milk fomula containing NMN (nutritional composition other than NMN is identical to commercial infant milk fomula) for 4 weeks after discharge from hospital

Interventions/Control_2

Control infant milk fomula group
- consume control infant milk fomula without NMN (commercial infant milk fomula) for 4 weeks after discharge from hospital

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Infants who are born between 28 and 37 weeks of gestation and their mothers aged of 18 years or older
2. Infants who are hospitalized but healthy and expected to have a normal life after discharge from hospital, and their mother
3. Mixed or artificially-fed infants and their mothers
4. Infants for whom the nutritional composition of infant milk fomula is suitable as a supplement to insufficient breast milk, and their mother
5. Infants whose mother and regal representatives (persons with parental authority) give the consent to participate in this study in written form after full explanation and full understanding of this study, and their mother theirselves

Key exclusion criteria

1. Infants with serious infection and their mothers
2. Infants with serious diseases and their mothers
3. Infants with other conditions that the responsible investigator or subinvestigators judge inappropriate to participate in this study

Target sample size

44


Research contact person

Name of lead principal investigator

1st name Hiromichi
Middle name
Last name Shoji

Organization

Juntendo University Hospital

Division name

Department of Pediatrics and Adolescent Medicine

Zip code

113-8431

Address

3-1-3, Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

hshoji@juntendo.ac.jp


Public contact

Name of contact person

1st name Arata
Middle name
Last name Yoneda

Organization

EviPRO Co., Ltd.

Division name

Clinical Study Support Division

Zip code

101-0032

Address

KDX Iwamoto-cho Building 2F, Iwamoto-cho 3-11-9, Chiyoda, Tokyo

TEL

03-5829-4110

Homepage URL


Email

yoneda_arata@evipro.co.jp


Sponsor or person

Institute

Juntendo University Hospital

Institute

Department

Personal name



Funding Source

Organization

Meiji Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee, Faculty of Medicine, Juntendo University

Address

3-1-3, Hongo, Bunkyo-ku, Tokyo

Tel

03-5802-1584

Email

hongo-rinri@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 04 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2024 Year 03 Month 26 Day

Date of IRB

2024 Year 04 Month 16 Day

Anticipated trial start date

2024 Year 04 Month 18 Day

Last follow-up date

2025 Year 02 Month 07 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 04 Month 18 Day

Last modified on

2024 Year 04 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061871


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name